Shares in regenerative medicine business Admedus Ltd (ASX: AHZ) are down 10% to 35 cents today and 52% lower over 2016 after the company revealed more big cash outflows for the quarter ending March 31 2016.
For the period Admedus posted a net operating cash outflow of $5.8 million with cash on hand at quarter end of $13 million. The large cash outflows and dwindling cash balance suggests the company may need to raise capital again within the next year unless it can dramatically reverse its fortunes.
Admedus has been investing a lot of capital all around the world in marketing and selling its regenerative heart patch named Cardiocel, although sales have not taken off as hoped. In fact for the most recent quarter total company receipts from customers are stated at $3.35 million, which is lower than the $3.48 million recorded for the prior quarter ending December 31 2015.
It’s not hard to see why investors are heading for the exits then, as CardioCel sales were only “up slightly” on the previous period despite management’s strategy to spend big to promote sales.
It was also revealed that executive management’s remuneration would be reduced by a minimum of 10% going forward, as part of cost-cutting plans that the company may be taking too late in the day.
In my opinion the shares remain a sell as its CardioCel product fails to take off and the cash outflows remain large compared to how much cash the company has to fund itself through the rest of 2016.
If you’re looking for small-cap medical device businesses then it would be far better to consider sleep treatment specialist Somnomed Limited (ASX: SOM), or disinfectant specialist Nanosonics Ltd (ASX: NAN). Both are well managed, growing sales quickly and cash flow positive, I expect their share prices could continue to travel in the opposite direction to Admedus over 2016.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
Motley Fool contributor Tom Richardson has no position in any stocks mentioned.
You can find Tom on Twitter @tommyr345
The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- On a serendipitous day, Tom Richardson is leaving the building – December 17, 2019 11:55am
- Why Aerometrex shares have doubled their IPO price – December 16, 2019 4:32pm
- Why the National Veterinary Care share price is going nuts today – December 16, 2019 3:39pm